Alessandrino E P, Orlandi E, Brusamolino E, Lazzarino M, Bernasconi C
Am J Hematol. 1985 Oct;20(2):191-3. doi: 10.1002/ajh.2830200215.
Low-dose arabinosyl cytosine (ARA-C) was tested in 15 patients with acute leukemia after a myelodysplastic syndrome (MDS) and in six elderly patients with acute nonlymphoid leukemia (ANLL). The drug was given subcutaneously at 10 mg/m2, every 12 hr for 2 weeks, every 28 days. The overall response rate was 19% (one complete remission, three partial responses), and the median duration of response was 4 months. No particular features at diagnosis were predictive of response. Pancytopenia and marrow hypoplasia occurred after 44 (78%) of 56 courses of therapy and were more severe in nonresponders. Four patients died during the aplasia following ARA-C therapy. Subcutaneous low-dose ARA-C was of limited benefit and bore a noticeable hematologic toxicity.
对15例骨髓增生异常综合征（MDS）后发生急性白血病的患者以及6例老年急性非淋巴细胞白血病（ANLL）患者进行了小剂量阿糖胞苷（ARA-C）治疗试验。药物以10mg/m²的剂量皮下注射，每12小时一次，持续2周，每28天重复一次。总缓解率为19%（1例完全缓解，3例部分缓解），中位缓解持续时间为4个月。诊断时没有特定特征可预测疗效。56个疗程的治疗中有44例（78%）出现全血细胞减少和骨髓发育不全，且在无反应者中更为严重。4例患者在ARA-C治疗后的再生障碍期死亡。皮下注射小剂量ARA-C益处有限，且有明显的血液学毒性。
